UY32592A - Métodos y reactivos para una transferencia génica eficaz y dirigida a monocitos y macrófagos - Google Patents

Métodos y reactivos para una transferencia génica eficaz y dirigida a monocitos y macrófagos

Info

Publication number
UY32592A
UY32592A UY0001032592A UY32592A UY32592A UY 32592 A UY32592 A UY 32592A UY 0001032592 A UY0001032592 A UY 0001032592A UY 32592 A UY32592 A UY 32592A UY 32592 A UY32592 A UY 32592A
Authority
UY
Uruguay
Prior art keywords
macrophages
monocits
reagents
directed
methods
Prior art date
Application number
UY0001032592A
Other languages
English (en)
Inventor
Miquel Angel Gassull Duro
Adolfo Rio Fernandez
Ester Fernandez Gimeno
Miguel Chillon Rodriguez
Original Assignee
Grifols Sa
Univ Barcelona Autonoma
Fundacio Inst D Investigacio En Ciencies De La Salut Germans Trias I Pujol
Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Sa, Univ Barcelona Autonoma, Fundacio Inst D Investigacio En Ciencies De La Salut Germans Trias I Pujol, Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats filed Critical Grifols Sa
Publication of UY32592A publication Critical patent/UY32592A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona un vector útil y bioseguro para transferir material genético a células mononucleares CD14+ (monocitos y macrófagos derivados de monocitos) de una manera eficaz y específica. La realización de la invención hace uso de los vectores de adenovirus 5 humano quimérico que portan la fibra corta de Ad40 enterotrópico para transferir material genético a las células mononucleares CD14+ diana.
UY0001032592A 2009-04-29 2010-04-29 Métodos y reactivos para una transferencia génica eficaz y dirigida a monocitos y macrófagos UY32592A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09159001A EP2248903A1 (en) 2009-04-29 2009-04-29 Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages

Publications (1)

Publication Number Publication Date
UY32592A true UY32592A (es) 2010-11-30

Family

ID=40971328

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032592A UY32592A (es) 2009-04-29 2010-04-29 Métodos y reactivos para una transferencia génica eficaz y dirigida a monocitos y macrófagos

Country Status (13)

Country Link
US (2) US20120045389A1 (es)
EP (3) EP2248903A1 (es)
AR (1) AR081354A1 (es)
AU (2) AU2010243566A1 (es)
BR (1) BRPI1016241A2 (es)
CA (1) CA2758592C (es)
ES (1) ES2550834T3 (es)
HU (1) HUE027887T2 (es)
IL (1) IL215688A (es)
MX (1) MX2011011410A (es)
PT (1) PT2695945E (es)
UY (1) UY32592A (es)
WO (1) WO2010125115A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
AU2014201381B2 (en) * 2012-02-14 2014-05-15 Loma Linda University Agents and method for treating inflammation-related conditions and diseases
CA2850380C (en) 2012-02-14 2015-08-18 Loma Linda University Agents and method for treating inflammation-related conditions and diseases
WO2013123298A1 (en) 2012-02-17 2013-08-22 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
GB201504251D0 (en) * 2015-03-13 2015-04-29 Virttu Biolog Ltd And University Of Sheffield The Oncolytic herpes simplex virus infected cells
BR112022003970A2 (pt) * 2019-09-03 2022-06-21 Myeloid Therapeutics Inc Métodos e composições para integração genômica
WO2021119538A1 (en) * 2019-12-11 2021-06-17 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
US20210317170A1 (en) * 2020-04-14 2021-10-14 Ut-Battelle, Llc Compositions and methods for drug delivery and treating viral infections
EP4240367A2 (en) 2020-11-04 2023-09-13 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
KR20240037192A (ko) * 2021-05-11 2024-03-21 마이얼로이드 테라퓨틱스, 인크. 게놈 통합을 위한 방법 및 조성물
CN115747170B (zh) * 2022-08-29 2023-08-04 四川大学 一种豇豆褪绿斑驳病毒-多肽复合物及其在骨质疏松治疗中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
KR970005042B1 (ko) 1993-02-09 1997-04-11 한일합성섬유공업 주식회사 종양괴사인자-알파 뮤테인
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
NZ500791A (en) 1997-05-08 2002-10-25 Genetic Therapy Inc Gene transfer with adenoviruses having modified fiber proteins
BR9809173A (pt) 1997-05-28 2000-08-01 Genvec Inc Adenovìrus alternativamente direcionados
US20050084966A1 (en) 1999-04-20 2005-04-21 Edelson Richard L. Methods for inducing the differentiation of blood monocytes into functional dendritic cells
CN1359391A (zh) 1999-07-06 2002-07-17 哥德－A－基因股份公司 重组腺病毒
CA2407518A1 (en) 2000-04-26 2001-11-01 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
AU2002223556A1 (en) * 2000-09-20 2002-04-02 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
AU2003210661A1 (en) * 2002-01-24 2003-09-02 Novartis Ag Fiber shaft modifications for efficient targeting
US20040167088A1 (en) * 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
CA2527954A1 (en) * 2003-06-11 2004-12-23 The Scripps Research Institute Modified fiber proteins for efficient receptor binding
GR20060100496A (el) * 2006-09-01 2008-04-15 Παρθενιος Μπουλικας ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
US20080311145A1 (en) 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics

Also Published As

Publication number Publication date
AU2014203841A8 (en) 2016-09-29
AU2014203841A1 (en) 2014-07-31
EP2248903A1 (en) 2010-11-10
PT2695945E (pt) 2015-11-16
AR081354A1 (es) 2012-08-29
CA2758592C (en) 2015-12-15
EP2424998A1 (en) 2012-03-07
CA2758592A1 (en) 2010-11-04
EP2695945A1 (en) 2014-02-12
EP2695945B1 (en) 2015-07-22
IL215688A (en) 2015-09-24
MX2011011410A (es) 2012-02-13
AU2010243566A1 (en) 2011-09-15
WO2010125115A1 (en) 2010-11-04
US20150174257A1 (en) 2015-06-25
EP2695945B9 (en) 2015-11-11
ES2550834T3 (es) 2015-11-12
AU2014203841B2 (en) 2016-03-31
US20120045389A1 (en) 2012-02-23
AU2014203841B8 (en) 2016-09-29
IL215688A0 (en) 2012-01-31
BRPI1016241A2 (pt) 2015-09-01
HUE027887T2 (en) 2016-10-28

Similar Documents

Publication Publication Date Title
UY32592A (es) Métodos y reactivos para una transferencia génica eficaz y dirigida a monocitos y macrófagos
MX2022009512A (es) Alteracion dirigida del receptor celular del complejo mayor de histocompatibilidad (mhc).
CO6670523A2 (es) Anticuerpos específicos para proteína de activación fibroblástica (fap), polinucleotidos que codifican dichos anticuerpos, y vectores y células huesped que comprenden dichos nucleótidos
AR080009A1 (es) Alteracion genomica objetivo utilizando nucleasas de dedos de zinc
MY180473A (en) Imaging and evaluating embryos, oocytes, and stem cells
BR112014008167A2 (pt) affenadenovirus (gorilla) ou vetores adenovirais e métodos de uso
CO6362050A2 (es) Vectores de terapia de gen y desaminasas citosina
CR20140318A (es) Composiciones intranasales de dexmedetomidina y métodos de uso de ellas
AR071242A1 (es) Anticuerpos anti-cd37
UY34484A (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
AR059257A1 (es) Genes para mejorar la eficiencia de la utilizacion de nitrogeno en los cultivos
GB201308243D0 (en) High-throughput immune sequencing
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
MY154956A (en) Chimeric adenoviral vectors
BR112014008249A2 (pt) affenadenovirus (gorilla) ou vetores adenovirais e métodos de uso
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
ES2479542T1 (es) Métodos y composiciones para su uso en terapias celulares
CU24405B1 (es) Proteínas de variantes de secuencias de aminoácidos de cry1da1 activas para lepidópteros
CL2009001643S1 (es) Unidad aritmetica y de control para videojuego o similar, de cuerpo paralelepipedico rectangular de sector frontal mas arriba que el sector posterior; el sector posterior inferior tiene en su cara frontal cuatro ranuras circulares, las centrales de menor dimension.
MD20130098A2 (ro) Test pentru determinarea lizil oxidazei-2 şi metode de utilizare a acestuia
MX2013006188A (es) Agentes de generacion de imagenes pet de apoptosis.
FI20095751A (fi) Ei Ad5 adenoviraaliset vektorit ja niihin liittyvät menetelmät ja käytöt
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
AR062145A1 (es) Metoods y composiciones para aumentar el tropismo tisular de vectores adenovirales recombinantes

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127